Focused On-demand Library for S-adenosylmethionine synthase isoform type-2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P31153

UPID:

METK2_HUMAN

Alternative names:

Methionine adenosyltransferase 2; Methionine adenosyltransferase II

Alternative UPACC:

P31153; A8K511; B4DN45; D6W5L1; Q53SP5

Background:

S-adenosylmethionine synthase isoform type-2, also known as Methionine adenosyltransferase 2, plays a pivotal role in cellular metabolism. It catalyzes the essential reaction of methionine and ATP to form S-adenosylmethionine (AdoMet), a critical methyl donor involved in numerous metabolic processes. This enzyme's activity is crucial for the synthesis of polyamines, nucleic acids, proteins, and lipids.

Therapeutic significance:

Understanding the role of S-adenosylmethionine synthase isoform type-2 could open doors to potential therapeutic strategies. Its central role in methylation processes makes it a potential target for interventions in metabolic disorders, offering a promising avenue for drug discovery and development.